Last reviewed · How we verify
NCT06001060
Distinct Alterations in Gut Microbiota Composition Among Women of Reproductive Age With Elevated Homocysteine Levels.
trial in Recurrent Miscarriage in 38 participants. Completed in 1 May 2023.
20 December 2022
Quick facts
| Lead sponsor | First People's Hospital of Hangzhou |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 38 |
| Start date | 1 October 2022 |
| Primary completion | 20 December 2022 |
| Estimated completion | 1 May 2023 |
| Sites | 1 location across China |
Conditions studied
- Recurrent Miscarriage — all drugs for Recurrent Miscarriage →
Sponsor
First People's Hospital of Hangzhou
Who can join
Adults 25 to 35, female only, with Recurrent Miscarriage. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to test the alterations of gut microbiota composition among women of reproductive age with elevated homocysteine levels. The main question it aims to answer is: • the relationship between gut microbiota composition and recurrent abortion. Participants will provide their stool samples to be detected the composition of gut microbiota. . Researchers will compare women of reproductive age with normal homocysteine levels to see if any bacteria were involved in recurrent miscarriages.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06001060
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Recurrent Miscarriage
Currently open trials in the same condition.
- NCT06826365 — Immune Cell Populations in the Endometrium · recruiting
- NCT06356792 — Obstetrics , Prenatal Outcomes in Recurrent Miscarriage · recruiting
- NCT06163092 — Chronic Endometritis and Benefits of Antibiotics in Women With Recurrent Miscarriage · recruiting
- NCT05725512 — Prednisolone Administration in Patients With Unexplained REcurrent MIscarriages · Phase 4 · recruiting
- NCT03902912 — Effect of Prednisolone Treatment on Uterine Natural Killer Cells · Phase 3 · recruiting
Other First People's Hospital of Hangzhou trials
Trials by the same sponsor.
- NCT07507825 — Exploratory Study of Venetoclax, Homoharringtonine, Azacitidine Plus G-CSF for Newly Diagnosed AML (VHAG) · Phase 2 · not yet recruiting
- NCT07390981 — Intradermal Acupuncture for Assisting SSRI Dose Reduction in Major Depressive Disorder · NA · not yet recruiting
- NCT07242443 — Tegoprazan Plus Amoxicillin BID vs TID Regimens for H. Pylori Eradication（Frequency Adjusted Same-dose Therapy for H. Py · Phase 4 · not yet recruiting
- NCT07207278 — Multi Omics Molecular Characteristics and Immunophenotyping of Lung Signet Ring Cell Carcinoma · recruiting
- NCT06933992 — Safety and Efficacy of Chocolate Balloon Catheter in Peripheral Arterial Disease (CHOCO-PAD) · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06001060 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by First People's Hospital of Hangzhou
- Last refreshed: 21 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06001060.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing